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Lymphopenia (, 1Giga/L) detected before initiation of chemotherapy is a predictive factor for death in metastatic solid
tumors. Combinatorial T cell repertoire (TCR) diversity was investigated and tested either alone or in combination with
lymphopenia as a prognostic factor at diagnosis for overall survival (OS) in metastatic breast cancer (MBC) patients. The
combinatorial TCR diversity was measured by semi quantitative multi-N-plex PCR on blood samples before the initiation
of the first line chemotherapy in a development (n = 66) and validation (n = 67) MBC patient cohorts. A prognostic score,
combining lymphocyte count and TCR diversity was evaluated. Univariate and multivariate analyses of prognostic factors
for OS were performed in both cohorts. Lymphopenia and severe restriction of TCR diversity called “divpenia” (diversity
# 33%) were independently associated with shorter OS. Lympho-divpenia combining lymphopenia and severe divpenia
accurately identified patients with poor OS in both cohorts (7.6 and 10.6 vs 24.5 and 22.9 mo). In multivariate analysis
including other prognostic clinical factors, lympho-divpenia was found to be an independent prognostic factor in the
pooled cohort (p = 0.005) along with lack of HER2 and hormonal receptors expression (p = 0.011) and anemia (p = 0.009).
Lympho-divpenia is a novel prognostic factor that will be used to improve quality of MBC patients’ medical care.
Introduction
Numerous studies have shown an impact of immune system
status on cancer patients’ outcomes. In a series of studies gather-
ing more than 3,000 patients, our group demonstrated that
lymphopenia is observed in 20–25% of patients with advanced
cancers, including 20% of untreated metastatic breast cancer
(MBC) patients.
1-4 All lymphocyte compartments are affected
including CD4
+ and CD8
+ T lymphocytes, NK cells, and B
lymphocytes.
3 Importantly, in MBC patients lymphopenia in
combination with PS . 1, is associated with a 20% risk of early
death at 1mo and 50% risk at 3mo.
3,5,6 In addition, lymphopenia
is also associated with an increased risk of disease progression and
worse long-term survival in three prospectively collected series
of patients with MBC at first line, along with non-Hodgkin
lymphoma, and soft tissue sarcomas.
6
Several studies have shown the presence and function of
immune cells in solid tumors that may promote both humoral
and cellular antitumor immune responses, contributing to tumor
control. Indeed, high numbers of CD8
+ T cells infiltrating breast
tumor predict favorable clinical outcome.
7 However, tumors
develop escape mechanisms including production of immuno-
suppressive cytokines, alteration of dendritic cell subsets differen-
tiation or function,
8-10 and recruitment of immunosuppressive
regulatory T-cells (Treg).
11,12
The recent success of immunotherapy based on anti CTLA-4
antibodies inducing increased overall survival (OS)
13 in advanced
melanoma confirms the relevance of T cell based anti tumor
immunity (for review, see ref. 14) and suggests that education and
activation of immune system could promote tumor control.
The T-cell receptor (TCR) combinatorial diversity results from
mechanisms by which exons encoding TCR variable regions are
assembled in developing T lymphocytes from germline variable
(V), diversity (D), and joining (J) gene segments.
15,16 Genomic
V(D)J rearrangements leading to combinatorial diversity is of
fundamental importance for the generation of diverse antigen
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receptor repertoires.
17-19 Several studies demonstrate the impor-
tance of this diversity in infectious diseases and in anti-tumor
responses. Indeed, constriction of the immune TCR repertoire
has been associated with progression in AIDS.
20 In melanoma,
a progressive widening of the repertoire diversity under chemo-
immunotherapy treatment was accompanied by high avidity and
tumor reactivity of Melan-A-specific T-cell clones.
21
The objective of this study was to assess the impact of the
quality of the immune system in MBC patients’ outcomes.
Here we demonstrate that a composite score called NDL
(Numeration and Diversity of Lymphocytes), combining lympho-
cyte count and TCR diversity, allowed the identification of a
subgroup of MBC patients with poor outcome.
Results
Patients’ characteristics. Table 1 describes the patients’ charac-
teristics in cohorts A and B. Both cohorts were similar except for
higher proportion of triple negative (TN) MBC patients in cohort
B (22% vs. 8%). None of the patients of cohort A was treated
with bevacizumab, whereas 39% of patients from cohort B
received bevacizumab-based chemotherapy. All patients with
overexpressing HER2/Neu tumors were treated with trastuzu-
mab-based chemotherapy. Median follow-up was respectively
18.8 and 14.3 mo in the cohort A and B.
Prognostic value of lymphopenia. In univariate analysis
(Table 2), PS . 1 (p = 0.03), liver metastasis (p = 0.02) and
hemoglobin , 11.5 g/dL (p = 0?003) were associated with poor
prognosis in cohort A, while LDH level was the only prognostic
factor in cohort B.
The incidence of lymphopenia (, 1 Giga/L) was 39% and
45% respectively for cohorts A and B higher than in previous
series.
1-4 In both cohorts, lymphopenia was associated with OS,
with a median OS of 11.2 and 10.4 mo, vs. 25.1 and 24.5 mo
for patients with lymphocyte count $ 1Giga/L, in cohort A
and B respectively (Fig.1A and B). The difference was statisti-
cally significant in cohort B (p = 0.0002) but not in cohort A
(p = 0.210).
Prognostic value of low TCR diversity (divpenia). Analysis
of TCR diversity on 26 healthy subjects showed a highly
homogenous diversity (median = 67%; range [59–77]) (Fig.1C).
By contrast, TCR diversity in both MBC patients cohorts
demonstrated reduced and highly dispersed diversity (for cohort
A: median = 46.4%, range [1.1–83.7]; for cohort B: median =
47.46%, range [6.2–70.3]). Regardless the lymphocyte count,
TCR diversity varied substantially between patients.
In cohort A, divpenia (# 33%) was correlated with low
hemoglobin level (55% of divpenic patients had also anemia,
p = 0.022, khi-deux Pearson), lymphopenia (50% of divpenic
patients were also lymphopenic, p = 0.026). Conversely, in cohort
B, divpenia was found associated with age (50% of divpenic
patients were $ 60 y old, p = 0.007), number of metastatic sites
(p , 10
24) and liver metastasis (44% of divpenic patients had
liver metastasis, p = 0.027).
In cohort A, divpenia was associated with poor prognosis
(p = 0.038) (Fig.1D) with a median OS of 9.7 mo for divpenic
Table1. Characteristics of the two independent cohorts
Cohort A (n = 66) Cohort B (n = 67)
n%n %
Age (years) Median (range) 59.9 (36.5–84.1) 56.9 (34.7–79.9)
Menopause no 35 53.03 19 28.78
yes 31 46.96 47 71.21
Adjuvant chemotherapy no 25 37.87 23 34.33
yes 41 62.12 44 65.67
Adjuvant hormonotherapy no 37 56.06 35 52.24
yes 29 43.93 32 47.76
Adjuvant Avastin no - - 36 58.06
yes - - 26 41.94
PS 0/1 51 72.27 42 62.68
. 1 15 22.72 25 37.32
ER No 15 23.07 21 31.34
yes 50 76.92 46 68.66
PgR no 20 30.30 33 49.25
yes 44 66.66 34 50.75
Her2/neu no 46 79.31 52 81.25
yes 12 20.68 12 18.75
Triple Negative (TNBT) no 60 92.30 52 77.61
yes 5 7.69 15 22.39
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patients vs. 21.7mo for non-divpenic patients. The difference was
not statistically different in cohort B (Fig.1E).
Prognostic value of lympho-divpenia. As shown in Figure2A,
within lymphopenic patients, divpenia can identify patients with
a reduced median OS (7.6 mo for divpenic patients compared
with 24.4mo for non divpenic patients p = 0.018). However,
divpenia had no impact for non-lymphopenic patients (Fig.2B).
An interaction between these two variables was demonstrated
using a Cox model and the variable (lymphopenia  divpenia) has
a stronger impact on OS than the two independently [p = 0.001,
HR = 3.108, CI95% (1.573–6.014)].
NDL analysis on healthy subjects showed only non-lymphopenic
and non-divpenic subjects (Fig.3A). In contrast, MBC patients
from cohorts A (Fig.3B) and B (Fig.3C) were distributed in all
four NDL compartments: a similar low lymphocyte count, was
either associated with a low TCR diversity or a diverse TCR
repertoire. Conversely, normal lymphocyte count was associated
with low TCR diversity or normal diversity. Interestingly,
lympho-divpenic patients (NDL score 1) had poor OS in cohort
A [median OS was 7.6mo compared with 24.4 for the
non-lympho-divpenic patients (p = 0.0006)] (Fig.3D) and
cohort B [median OS of 10.6mo vs 22.9 for the non-lympho-
divpenic patients (p = 0.0035)] (Fig.3E).
Univariate and multivariate analysis for the pooled cohorts.
We pooled patients of cohorts A and B. In univariate analysis,
lympho-divpenia appears as the most significant predictive
factor of poor prognosis (p , 10
24)( Table S1) together with
PS . 1 (p = 0.0054), anemia (p = 0.0005) and lymphopenia
(p = 0.0011). Divpenia tended toward significance (p = 0.073)
(Table S1). Median OS of patients with lympho-divpenia was
8.1mo compared with 23.6 mo for non-lympho-divpenic patients
(Fig.4A).
Interestingly, segregation of patients according to each NDL
score separately beside the small size of each part (Fig.4B)
demonstrated that lympho-divpenia (n = 21) as well as lympho-
penia only (n = 32) seems to be of poor prognosis in contrast to
divpenia alone (n = 17) or non lymphopenic nor divpenic patients
(n = 53).
In multivariate analysis, three factors were independently asso-
ciated with worse prognosis (2-fold increased hazard ratio of
Table2. Univariate analysis: Cox Model on overall survival on the two cohorts
cohort A cohort B
number HR CI (95%) p value number HR CI (95%) p value
Age (years) , 60 (R) 39 0.542 40 0.759
$ 60 27 1.207 [0.660–2.206] 27 0.907 [0.486–1.693]
Menopause no 35 0.139 19 0.030
yes 31 1.578 [0.862–2.886] 47 2.257 [1.081–4.716]
Hemoglobin (g/dl) $ 11.5 (R) 18 0.002 20 0.076
, 11.5 47 0.368 [0.198–0.685] 46 0.566 [0.301–1.562]
Number of metastatic sites 1/3 (R) 35 0.015 34 0.202
$ 4 31 2.134 [1.157–3.936] 33 1.493 [0.807–2.760]
PNN (Giga/L) $ 7.5 (R) 58 0.470 53 0.001
, 7.5 7 1.470 [0.517–4.178] 13 0.306 [0.151–0.621]
PS 0/1 (R) 51 0.025 42 0.105
. 1 15 2.105 [1.091–4.060] 25 1.662 [0.899–3.073]
Liver metastases no (R) 18 0.038 38 0.672
yes 48 2.266 [1.048–4.898] 29 1.140 [0.621–2.193]
Bone metastases no (R) 21 0.626 22 0.568
yes 45 1.182 [0.604–2.310] 45 0.831 [0.441–1.567]
Triple negative tumors no (R) 60 0.275 52 0.060
yes 5 1.960 [0.585–6.570] 15 1.981 [0.970–4.043]
LDH (Ul/ml) , 600 (R) 41 0.125 44 0.015
$ 600 13 1.779 [0.850–3.720] 23 3.500 [1.272–9.629]
TCR Diversity (%) . 33 (R) 44 0.042 43 0.643
# 33 22 1.907 [1.023–3.555] 16 1.183 [0.582–2.405]
Lymphocytes (Giga/L) $ 1 (R) 38 0.210 35 0.000
, 1 28 1.408 [0.802–2.685] 30 3.156 [1.720–6.547]
NDL 1 (R) 53 0.001 54 0.006
. 1 13 3.108 [1.573–6.140] 8 3.150 [1.395–7.110]
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Figure1. Overall survival of patients according to their baseline lymphocyte counts (, 1 Giga/L or $ 1Giga/L) for patients enrolled in cohort A (A) and
cohort B (B). Comparison of TCR diversity in healthy subjects and patients from cohorts A and B (C). Overall survival according to their baseline TCR
diversity (# 33% or . 33%) for patients enrolled in cohort A (D) and cohort B (E).
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Figure2. Overall survival according to baseline TCR diversity (# 33% or . 33%) in cohort A within lymphopenic patients (A) or non lymphopenic
patients (B).
Figure3. NDL representation on healthy subjects (n = 26) (A), cohort A (n = 66) (B) and cohort B (n = 67) (C). Overall survival according to their lympho-
divpenic status (NDL score 1) in the cohort A (n = 66) (D) and cohort B (n = 62) (E).
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death): anemia (HR = 2.08, p = 0.009), triple negative (TN)
tumors (HR = 2.56, p = 0.011) and lympho-divpenia (HR =
2.52, p = 0.005) (Table 3).
Discussion
In this study, we showed that lympho-divpenia identified a
subgroup of patients particularly at risk of early death (# 8mo)
that appears refractory to standard chemotherapy.
Immune status is now emerging as an essential biomarker of
the biology of the tumor and its microenvironment with a global
impact on patient outcome. On top of the well-documented
negative impact of lymphopenia on OS for MBC patients and
other advanced solid tumors,
6,22,23 these results further demon-
strate that TCR diversity is frequently reduced in a subset of
MBC patients and that divpenia may be assessed in clinic to better
define the treatment strategy.
Added value of the NDL to segregate patients. Lymphocyte
count and diversity are the two dimensions required for an
efficient immune response.
6,24 While a minimum number of
lymphocytes is required, TCR diversity could reflect the capacity
to recognize an antigen.
Lympho-divpenic patients cumulating a low lymphocyte
count and a low combinatorial TCR diversity highlighting a
profound immunodeficiency present a shorter OS.
Analysis of each NDL score separately suggests that lympho-
penia alone is of poorer prognosis than divpenia alone. This
observation will be confirmed in a larger cohort of MBC patients
under accrual. This will also be evaluated on metastatic lung
carcinoma currently enrolled in a prospective clinical trial
(LYMPHOS1: NCT01306188) to confirm the prognostic
value of lympho-divpenia in diverse clinical situations since we
demonstrated that lymphopenia has a negative impact in different
solid tumors.
6,23
Studying immune system will help to propose personalized
treatments that would limit toxic effects and improve life
expectancy. Indeed, NDL score will allow identification of
lympho-divpenic patients that will represent candidate for the
development of new strategies aiming at (1) reconstituting a
functional immune system prior to chemotherapy treatment or
(2) privileging targeted therapies over chemotherapies.
Different molecules have been developed and evaluated for
their ability to favor immune T-cells reconstitution. Whereas,
IL-2 was known to favor CD4
+ T-cell expansion, two clinical
trials (SILCAAT and ESPRIT) performed in HIV individuals
failed to demonstrate any clinical benefit, perhaps because of a
concomitant expansion of Treg endowed with immunosuppres-
sive functions.
25
In contrast, accumulated evidences in clinical trials, indicate
the potent lymphopoietic effect of rhIL-7 (CYT107, Cytheris),
on both CD4
+ and CD8
+ T-cells subsets excluding Treg
expressing low levels of IL-7Ra receptor.
26 Interestingly, in
HAART resistant HIV individuals presenting with low CD4
+
T cell counts (0,25 Giga/L), a short period of rhIL-7 treatment
increased and maintained their CD4
+ T cell pool above the
. 0,5 Giga/L threshold for one year.
27 Such long lasting effects
were also observed in lymphopenic cancer patients where T cell
Figure4. (A) Overall survival according to their lympho-divpenic status
(NDL score 1) on the pooled cohort (n = 123) (B) Overall survival
according to the different NDL scores i.e: lympho-divpenia (NDL score 1),
lymphopenia alone (NDL score 2), divpenia alone (NDL score 3) and
neither lymphopenia nor divpenia (NDL score 4).
Table3. Multivariate analysis in pooled cohort
HR CI 95% significance (p)
Hemoglobin
($ 11.5 vs , 11.5)(g/L)
0.481 [0.277–0.834] 0.009
Triple negative tumors
(Yes vs No)
2.563 [1.239–5.304] 0.011
NDL (. 1 vs 1) 2.521 [1.332–4.771] 0.005
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counts increased few weeks after the IL-7 cycle and remaind
stable.
6,24,28
IL-7 therapy could also favor TCR diversity as recently
demonstrated in HIV patients.
29 The impact of CYT-107 in the
restoring lymphocyte counts and TCR repertoire diversity
patients is currently under investigation in MBC in our institu-
tion in a randomized Phase II trial (ELYPSE 7 clinical trial,
NCT01368107).
Origin of lymphopenia and divpenia. It remains unclear
whether lymphopenia and divpenia are the cause or the con-
sequence of tumor aggressiveness. Both parameters could result
from the tumor burden and/or dissemination status as well as on
host characteristics (patient age or genetic polymorphisms).
As the study enrolled only previously untreated patients,
lymphopenia or divpenia do not result from previous exposure to
cytotoxic agents as described by others.
30,31
In the pooled series, lymphopenia correlated with patients’ age
analyzed as continuous variable (p = 0.04) and PS status (p =
0.001) and an inverse correlation was observed between TCR
diversity and age when tested as continuous variables (p = 0.001).
Thus reduced thymic function in elderly
32 may contribute to the
reduced number and TCR diversity of circulating lymphocytes in
tumor bearing patients. In this context, Mackall and colleagues
31
demonstrated the rapid CD4
+ T cell pool reconstitution in young
cancer patients treated with intensive chemotherapy. In contrast,
adults exhibit deficiencies in this pathway suggesting that rapid
T cell regeneration requires residual thymic function.
The quantification of total tumor burden at first relapse
remains yet difficult to assess but could be evaluated by the
number of metastatic sites. Whereas in the pooled cohort, no
correlation was observed between lymphopenia and number of
metastatic spreading, divpenia strongly correlated with the
number of metastatic sites involved (# 3v s. 3, p , 10
24)
suggesting association between divpenia and tumor aggressive-
ness and underlining the independence of the two dimensions
of both NDL parameters.
The influence of patients’ genetic polymorphisms on lympho-
cyte counts and diversity in cancer patients remains unknown.
Data reported in HIV patients strongly suggest the relevance of
genes products involved in T cell proliferation (IL-2, IL-2Rβ, IL-
2Rc, IL-15, IL-15Ra) or apoptotis (TRAIL, Bim, TNFa and
IFNc) in regulating the peripheral T-cell pool size during anti-
retroviral therapy. Indeed, number of polymorphisms in these
genes, alone or in combination, and several haplotypes were
found associated with the magnitude of CD4
+ T-cell recovery.
33
Analyses of polymorphisms may help to elucidate mechanisms
underlying lymphopenia in our study.
Lymphopenia and divpenia may result not only from reduced
thymic function but also from the destruction of lymphocytes
elicited by breast tumor cells expressing pro-apoptotic ligands,
34
a blockade of lymphocyte proliferation via inhibitory molecules
(PD-L1) expressed by tumor cells,
35 or a reduced capacity of
lymphocytes to respond to TCR stimulation due to an alteration
of f chain expression.
36 Soluble factors secreted or induced by
tumor cells may also impact systemic lymphopoiesis. Moreover,
this lymphopenia could also result from a chronic stimulation of
peripheral T cells favored by tumor cells leading to their deple-
tion by activation induced cell death (AICD).
37 In this context,
in HIV infection, CD4
+ lymphopenia resulted from AICD due
to chronic activation of the immune system by HIV infection,
endotoxinemia or other cues rather than a direct destruction of
infected CD4
+ T cells (for review see ref. 38).
To a lower extent, the mechanism of AICD may also culminate
in the loss of expanded specific T cell clones, favoring the
appearance of holes in the TCR diversity. In line with this
assumption, 36% of lymphopenic patients presented also an
altered TCR diversity (lympho-divpenia).
Materials and Methods
Patients. Sixty-six patients with MBC who received first-line
chemotherapy at Léon Bérard Cancer Center between 2004 and
2007 were enrolled in the development cohort (cohort A). A
validation cohort (cohort B) of 67 patients with MBC was
enrolled in a prospective clinical trial between 2006 and 2010.
Patients with a known HIV disease were excluded from these
two studies.
Control healthy subjects used for TCR diversity analyses were
recruited on the basis of absence of auto-immune or infectious
disease and cancer. Pregnant women, subjects recently vaccinated
or on steroids over the last 3mo were also excluded.
Previously validated prognostic factors were collected to
characterize both cohorts (age, menopausal status, performance
status (PS), hemoglobin, LDH, neutrophils (PNN), hormonal
receptor status (ER, PgR), Her2/neu amplification, metastatic
sites and number of metastatic sites).
Peripheral blood samples were collected for full blood count
evaluation before initiation of chemotherapy and cryo-preserved
(day 0).
Written informed consent was obtained from each patient. The
institutional ethics committee approved both study protocols
before implementation.
Combinatorial diversity analysis (Multiplexe PCR assay).
Human TCR diversity was measured using Human
ImmunTraCkeRβ
1 test (ImmunID Technologies; Grenoble,
France) on genomic DNA extracted using standard techniques
from total peripheral mononuclear cells. Multi-N-plex PCR was
performed using an upstream primer specific of all functional
members of a given TRBV family and a downstream primer
specific of a given TRBJ segment allowing the simultaneous
detection of several V–J rearrangements in the same reaction.
Twenty-three different reactions allow covering of all (276) the
possible rearrangements.
PCR products were generated using iProof enzyme (Bio-Rad)
with cycling condition as followed (98°C for 3 min, 98°C for
20 sec, 72°C for 20 sec and 72°C for 3min 30 sec and reducing
the annealing temperature by one degree every cycle until reached
68°C which was then repeated 23 times. Finally one cycle of
10min at 72°C was performed). PCR reactions were stopped at
the exponential step of the PCR. Normalization was performed
on the actin gene amplified in the same PCR run. All V–J
products, with a maximum amplicon size of ~5kb, were separated
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according to their size on a 0.8% agarose gel, directly stained with
SyberGreen and quantified using a CCD camera (Vilbert
Lourmart; France). PCR signals were detected and analyzed
using the Constel’ID software (ImmunID Technologies).
Statistical analysis. In order to analyze TCR diversity impact
on clinical outcome, the study population was divided into tertiles
on the basis of the diversity. The threshold for the first tertile
corresponding to # 33% combinatorial diversity was called severe
“divpenia.”
Furthermore, we built a NDL score assessing the lymphocyte
count as a function of the combinatorial diversity. Four NDL
scores were defined using , 1 vs. $ 1 Giga/L for lymphocyte
count and # 33% vs. . 33% for diversity (Fig.4). Patients with
lymphopenia and divpenia were called “lympho-divpenia.”
Survival analysis. OS was defined as the time from patient’s
inclusion to the date of death or the date of the last follow-up
for alive patients. Survival distributions were estimated by the
Kaplan-Meier method.
39
Univariate analysis. To assess the relationship between OS
and all relevant biological and/or clinical data, reliable prognostic
factors were included in univariate Cox proportional hazard
regression model. Prognostic factors commonly used in previous
studies (e.g., PS, age, hemoglobin, LDH levels and PNN count)
were dichotomized using previously published cutoff. Lympho-
penia (, 1 Giga/L vs. $ 1 Giga/L) and TCR divpenia (# 33%
vs. . 33%) were also used as dichotomous variables. Candidate
prognostic factors with a 0.10 level of significance in univariate
analysis were then included in the multivariate analysis.
Multivariate model analysis. Independent prognostic variables
of OS were identified by a Cox regression analysis using a
backward selection procedure.
40 The added value of NDL in
the models was evaluated using a likelihood ratio test (LRT);
likelihood scores of the model evaluated with and without the
biomarker were compared, considering that lower likelihood
scores will indicate better fitting models.
41
All statistical analyses were performed independently by the
Léon Bérard Center biostatistic department using SAS v.9.2 pack-
age (Cary) and ImmunID Technologies using R (GNU Public).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
This work was financially supported by CLARA (Lymphos’1),
FUI projects (PLATINE, DIVRESCUE) and INCa translational
program (Breast Immune). M.M. is a grant holder of the ANRT
with financial support of ImmunID. For his last PhD year, he has
been financed by an ARC students’ fellowship. The authors
would like to thank the institutional Biological Research Center
from the Centre Léon Bérard for providing us with patients
PBMC.
Supplemental Material
Supplemental materials may be found here:
http://www.landesbioscience.com/journals/oncoimmunology/
article/19545/
References
1. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour
D, Lasset C, et al. Early lymphopenia after cytotoxic
chemotherapy as a risk factor for febrile neutropenia. J
Clin Oncol 1996; 14:636-43; PMID:8636781
2. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud
A, Chevreau C, et al. A risk model for thrombocyto-
penia requiring platelet transfusion after cytotoxic
chemotherapy. Blood 1998; 92:405-10; PMID:
9657738
3. Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-
Vermare N, Menetrier-Caux C, et al. CD4 lymphopenia
as a risk factor for febrile neutropenia and early death
after cytotoxic chemotherapy in adult patients with
cancer. Cancer 2004; 101:2675-80; PMID:15503313;
http://dx.doi.org/10.1002/cncr.20688
4. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip
I, Clapisson G, et al & ELYPSE study group. Baseline
and early lymphopenia predict for the risk of febrile
neutropenia after chemotherapy. Br J Cancer 2003;
88:181-6; PMID:12610500; http://dx.doi.org/10.
1038/sj.bjc.6600724
5. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C,
Biron P, Sebban C, et al & ELYPSE Study Group.
Identification of patients at risk for early death after
conventional chemotherapy in solid tumours and
lymphomas. Br J Cancer 2001; 85:816-22; PMID:
11556830; http://dx.doi.org/10.1054/bjoc.2001.2011
6. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban
C, Le Cesne A, Judson I, et al & European Organi-
zation for Research and Treatment of Cancer Soft
Tissue and Bone Sarcoma Group. Lymphopenia as a
prognostic factor for overall survival in advanced
carcinomas, sarcomas, and lymphomas. Cancer Res
2009; 69:5383-91; PMID:19549917; http://dx.doi.
org/10.1158/0008-5472.CAN-08-3845
7. Mahmoud SM, Paish EC, Powe DG, Macmillan RD,
Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+
lymphocytes predict clinical outcome in breast cancer. J
Clin Oncol 2011; 29:1949-55; PMID:21483002;
http://dx.doi.org/10.1200/JCO.2010.30.5037
8. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M,
Treilleux I, Bajard A, et al. Quantitative and functional
alterations of plasmacytoid dendritic cells contribute to
immune tolerance in ovarian cancer. Cancer Res 2011;
71:5423-34; PMID:21697280; http://dx.doi.org/10.
1158/0008-5472.CAN-11-0367
9. Menetrier-Caux C, Montmain G, Dieu MC, Bain C,
Favrot MC, Caux C, et al. Inhibition of the differ-
entiation of dendritic cells from CD34(+) progenitors
by tumor cells: role of interleukin-6 and macrophage
colony-stimulating factor. Blood 1998; 92:4778-91;
PMID:9845545
10. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard
I, Bachelot T, Guastalla JP, et al. Dendritic cell
infiltration and prognosis of early stage breast cancer.
Clin Cancer Res 2004; 10:7466-74; PMID:15569976;
http://dx.doi.org/10.1158/1078-0432.CCR-04-0684
11. Faget J, Biota C, Bachelot T, Gobert M, Treilleux I,
Goutagny N, et al. Early detection of tumor cells by
innate immune cells leads to T(reg) recruitment
through CCL22 production by tumor cells. Cancer
Res 2011; 71:6143-52; PMID:21852386; http://dx.
doi.org/10.1158/0008-5472.CAN-11-0573
12. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot
T, Goddard-Leon S, Arfi V, et al. Regulatory T cells
recruited through CCL22/CCR4 are selectively acti-
vated in lymphoid infiltrates surrounding primary
breast tumors and lead to an adverse clinical outcome.
Cancer Res 2009; 69:2000-9; PMID:19244125;
http://dx.doi.org/10.1158/0008-5472.CAN-08-2360
13. Hodi FS, O’Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, et al. Improved survival with
ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010; 363:711-23; PMID:20525992;
http://dx.doi.org/10.1056/NEJMoa1003466
14. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4
antibody therapy: immune monitoring during clinical
development of a novel immunotherapy. Semin Oncol
2010; 37:473-84; PMID:21074063; http://dx.doi.org/
10.1053/j.seminoncol.2010.09.001
15. Hesslein DG, Schatz DG. Factors and forces control-
ling V(D)J recombination. Adv Immunol 2001; 78:
169-232; PMID:11432204; http://dx.doi.org/10.
1016/S0065-2776(01)78004-2
16. Tonegawa S. Somatic generation of antibody diversity.
Nature 1983; 302:575-81; PMID:6300689; http://dx.
doi.org/10.1038/302575a0
17. Marodon G, Desjardins D, Mercey L, Baillou C, Parent
P, Manuel M, et al. High diversity of the immune
repertoire in humanized NOD.SCID.gamma c-/- mice.
Eur J Immunol 2009; 39:2136-45; PMID:19572320;
http://dx.doi.org/10.1002/eji.200939480
18. Pasqual N, Gallagher M, Aude-Garcia C, Loiodice M,
Thuderoz F, Demongeot J, et al. Quantitative and
qualitative changes in V-J alpha rearrangements during
mouse thymocytes differentiation: implication for a
limited T cell receptor alpha chain repertoire. J Exp
Med 2002; 196:1163-73; PMID:12417627; http://dx.
doi.org/10.1084/jem.20021074
www.landesbioscience.com OncoImmunology 439© 2012 Landes Bioscience.
Do not distribute.
19. Pham HP, Manuel M, Petit N, Klatzmann D, Cohen-
Kaminsky S, Six A, et al. Half of the T-cell repertoire
combinatorial diversity is genetically determined in
humans and humanized mice. Eur J Immunol 2011;
Epub ahead of print; PMID:22105329; http://dx.doi.
org/10.1002/eji.201141798.
20. Gorochov G, Neumann AU, Kereveur A, Parizot C,
Li T, Katlama C, et al. Perturbation of CD4+ and
CD8+ T-cell repertoires during progression to AIDS
and regulation of the CD4+ repertoire during antiviral
therapy. Nat Med 1998; 4:215-21; PMID:9461196;
http://dx.doi.org/10.1038/nm0298-215
21. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini
C, Gualtieri N, et al. Dacarbazine treatment before
peptide vaccination enlarges T-cell repertoire diversity
of melan-a-specific, tumor-reactive CTL in melanoma
patients. Cancer Res 2010; 70:7084-92; PMID:
20823160; http://dx.doi.org/10.1158/0008-5472.CAN-
10-1326
22. Capellino AR, Desposorio CR, Hurtado de Mendoza F,
et al. Lymphopenia and breast cancer subtypes as pro-
gnostic factors in patients with locally advanced breast
cancer. ASCO Meeting, 29 2011 e21100(Abstract)
23. Cézé N, Thibault G, Goujon G, Viguier J, Watier H,
Dorval E, et al. Pre-treatment lymphopenia as a pro-
gnostic biomarker in colorectal cancer patients receiving
chemotherapy. Cancer Chemother Pharmacol 2011;
68:1305-13; PMID:21448592; http://dx.doi.org/10.
1007/s00280-011-1610-3
24. Luo W, Liao WJ, Huang YT, Shi M, Zhang Y, Wen Q,
et al. Normalization of T cell receptor repertoire
diversity in patients with advanced colorectal cancer
who responded to chemotherapy. Cancer Sci 2011;
102:706-12; PMID:21235683; http://dx.doi.org/10.
1111/j.1349-7006.2011.01868.x
25. Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-
Petrini V, Targat B, et al. In vivo expansion of naive
and activated CD4+CD25+FOXP3+ regulatory T cell
populations in interleukin-2-treated HIV patients. Proc
Natl Acad Sci U S A 2010; 107:10632-7; PMID:
20498045; http://dx.doi.org/10.1073/pnas.1000027107
26. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu
S, et al. CD127 expression inversely correlates with
FoxP3 and suppressive function of human CD4+ T reg
cells. J Exp Med 2006; 203:1701-11; PMID:
16818678; http://dx.doi.org/10.1084/jem.20060772
27. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C,
Lelièvre JD, et al. Enhanced T cell recovery in HIV-1-
infected adults through IL-7 treatment. J Clin Invest
2009; 119:997-1007; PMID:19287090
28. Morre M, Beq S. Interleukin-7 and immune reconstitu-
tion in cancer patients: a new paradigm for dramatically
increasing overall survival. Targeted Oncology 2012;
7:55-68; PMID:2238042; http://dx.doi.org/10.1007/
s11523-012-0210-4
29. Sportès C, Hakim FT, Memon SA, Zhang H, Chua
KS, Brown MR, et al. Administration of rhIL-7 in
humans increases in vivo TCR repertoire diversity by
preferential expansion of naive T cell subsets. J Exp
Med 2008; 205:1701-14; PMID:18573906; http://dx.
doi.org/10.1084/jem.20071681
30. Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee
N, Zujewski J, et al. Constraints on CD4 recovery
postchemotherapy in adults: thymic insufficiency and
apoptotic decline of expanded peripheral CD4 cells.
Blood 1997; 90:3789-98; PMID:9345067
31. Mackall CL, Fleisher TA, Brown MR, Magrath IT,
Shad AT, Horowitz ME, et al. Lymphocyte depletion
during treatment with intensive chemotherapy for
cancer. Blood 1994; 84:2221-8; PMID:7919339
32. Ferrando-Martínez S, Franco JM, Hernandez A,
Ordoñez A, Gutierrez E, Abad A, et al. Thymopoiesis
in elderly human is associated with systemic inflam-
matory status. Age (Dordr) 2009; 31:87-97; PMID:
19507053; http://dx.doi.org/10.1007/s11357-008-
9084-x
33. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger
AA, D’Aquila RT, et al & AIDS Clinical Trials Group.
Immunogenetics of CD4 lymphocyte count recovery
during antiretroviral therapy: An AIDS Clinical Trials
Group study. J Infect Dis 2006; 194:1098-107; PMID:
16991084; http://dx.doi.org/10.1086/507313
34. Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, et al.
Functional polymorphisms in FAS and FASL contri-
bute to increased apoptosis of tumor infiltration
lymphocytes and risk of breast cancer. Carcinogenesis
2007; 28:1067-73; PMID:17183065; http://dx.doi.
org/10.1093/carcin/bgl250
35. Ghebeh H, Mohammed S, Al-Omair A, Qattan A,
Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T
lymphocyte-inhibitory molecule is expressed in breast
cancer patients with infiltrating ductal carcinoma:
correlation with important high-risk prognostic factors.
Neoplasia 2006; 8:190-8; PMID:16611412; http://dx.
doi.org/10.1593/neo.05733
36. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK,
Gooding W, Lotze M, et al. Decreased zeta chain
expression and apoptosis in CD3+ peripheral blood T
lymphocytes of patients with melanoma. Clin Cancer
Res 2001; 7(Suppl):947s-57s; PMID:11300496
37. Agrawal S, Marquet J, Delfau-Larue MH, Copie-
Bergman C, Jouault H, Reyes F, et al. CD3 hypo-
responsiveness and in vitro apoptosis are features of
T cells from both malignant and nonmalignant
secondary lymphoid organs. J Clin Invest 1998; 102:
1715-23; PMID:9802885; http://dx.doi.org/10.1172/
JCI3784
38. Grossman H. AIDS at 25: a quarter century of medical
miracles. MedGenMed 2006; 8:57; PMID:16926796
39. Meier F, Will S, Ellwanger U, Schlagenhauff B,
Schittek B, Rassner G, et al. Metastatic pathways and
time courses in the orderly progression of cutaneous
melanoma. Br J Dermatol 2002; 147:62-70; PMID:
12100186; http://dx.doi.org/10.1046/j.1365-2133.
2002.04867.x
40. Chen CH, George SL. The bootstrap and identifica-
tion of prognostic factors via Cox’s proportional hazards
regression model. Stat Med 1985; 4:39-46; PMID:
3857702; http://dx.doi.org/10.1002/sim.4780040107
41. Dahm PF, Gail MH, Rosenberg PS, Pee D. Deter-
mining the value of additional surrogate exposure data
for improving the estimate of an odds ratio. Stat Med
1995; 14:2581-98; PMID:8746890; http://dx.doi.org/
10.1002/sim.4780142307
440 OncoImmunology Volume 1 Issue 4